Auxilium Pharmaceuticals

Ownership

Private

Employees

~91

Therapeutic Areas

EndocrinologyRheumatologyDermatologyMen's Health

Stage

Commercial

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Modalities

Small moleculesimplantable therapeutics

Auxilium Pharmaceuticals General Information

Auxilium had a broad portfolio of 12 approved products before being acquired by Endo International in 2014

Contact Information

Website

https://www.orpha.net/en/institutions/legal-entity/371804

Primary Industry

Biotech

Corporate Office

Malvern, Pennsylvania
United States

Drug Pipeline

XIAFLEX

Commercial

Indications: Lorem ipsum dolor sit

Modality: Lorem ipsum

Drug Asset 2

Phase X

Indications: Lorem ipsum dolor sit

Modality: Lorem ipsum

Drug Asset 3

Phase X

Indications: Lorem ipsum dolor sit

Modality: Lorem ipsum

For full access to Auxilium Pharmaceuticals's pipeline data

Key Partnerships

Prasco (for Authorized Generic version of Testim)

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Auxilium Pharmaceuticals Funding

No funding data available

Early Stage VC (Series A)	04-Jun-2020	$38M	Completed	Phase 1
Seed Round	12-Feb-2019	$8.5M	Completed	Startup

Interested in comprehensive profile data?

We'll help you find what you need

To view Auxilium Pharmaceuticals's complete valuation and funding history, request access »

Auxilium Pharmaceuticals Financial Metrics